Melatonin: an anti-tumor agent for osteosarcoma
- 102 Downloads
Osteosarcoma is the most common bone tumors which consisted of malignant mesenchymal cells generating osteoid and immature bone. It has been showed that osteosarcoma is common in children and adolescents and shows high mortality rate. A variety of therapeutic approaches (i.e., resection surgery, combined with chemotherapy and radiotherapy) have been used as conventional treatments in patients with osteosarcoma. Despite several attempts to improve therapeutic response, the rate of survival for osteosarcoma has not changed during the past 3 decades. Therefore, the discovery and developing new effective therapeutic platforms are required. Along to the established anti-cancer agents, some physiological regulators such melatonin, have been emerged as new anti-cancer agents. Melatonin is an indolamine hormone which is secreted from the pineal glands during the night and acts as physiological regulator. Given that melatonin shows a wide spectrum anti-tumor impacts. Besides different biologic activities of melatonin (e.g., immunomodulation and antioxidant properties), melatonin has a crucial role in the formation of bones, and its deficiency could be directly related to bone cancers. Several in vitro and in vivo experiments evaluated the effects of melatonin on osteosarcoma and other types of bone cancer. Taken together, the results of these studies indicated that melatonin could be introduced as new therapeutic candidate or as adjuvant in combination with other anti-tumor agents in the treatment of osteosarcoma. Herein, we summarized the anti-tumor effects of melatonin for osteosarcoma cancer as well as its mechanism of action.
KeywordsOsteosarcoma Melatonin Therapy
vascular endothelial growth facto
nuclear factor kappa B
Osteosarcoma is known as the most common aggressive and malignant tumor from bone. It usually occurs in the metaphysis of long bones and happens predominantly in children and adolescents . Although the causes of osteosarcoma have not yet been fully elucidated, there is probably a correlation between the rate of bone growth during puberty and the incidence of this disease . It has also been seen that young patients with osteosarcoma are usually taller than healthy subjects in similar age groups [1, 3]. Osteosarcoma accounted for approximately 5% of childhood cancers and also almost 8.9% of childhood cancer-related deaths. The incidence of osteosarcoma is estimated at 5 per million people . Ewing sarcoma is another type of secondary bone cancer which occurred more often in adolescents . In this kind of cancer, the survival rate is about 50% in 5 years after the initial diagnosis .
Conventional therapies for osteosarcoma consisted of a combination of surgery and adjuvant and neoadjuvant chemotherapy . Given that before utilization of chemotherapy, less than a 20% survival rate in high-grade conventional osteosarcoma even with surgical amputation, revealing the existence of micrometastases before surgery . The low grade could be treated with excision alone and chemotherapy is avoided if final pathology confirms low grade .
Treatments that are used for bone cancers are not associated with effective results and are not able to increase the survival rate . On the other hand, the used therapeutic platforms are related to various side effects . Therefore, novel therapeutic approaches with less or no adverse effects are needed in the treatment of osteosarcoma patients .
Melatonin, N-acetyl-5-methoxy-tryptamine, plays significant roles in different physiological events such as regulating the sleep–wake cycle, declining of tumor progress, ameliorating of immune system actions, and control of homeostasis in the various tissues [11, 12]. Furthermore, melatonin acts as an antioxidant and oncostatic attributes . Several evidence revealed the repressing effects of melatonin against many types of tumors including breast, endometrium, prostate, ovary, intestine, and liver [14, 15, 16, 17, 18, 19]. Bone metabolism is related to the levels of melatonin which lead to the prevention of bone degradation and the progression of bone formation . Given that the reduction of melatonin levels in the specific time points, is associated with high incidence of osteosarcoma. Thus, it seems that melatonin acts as a potential anti-osteosarcoma. Here, we focused on osteosarcoma-related molecular mechanisms affected by melatonin. Moreover, we highlighted the different findings of pre-clinical researches on anti- osteosarcoma effects of melatonin.
Osteosarcoma pathogenesis: insights in molecular mechanisms
Osteosarcoma is associated with a complex of numerical and structural chromosomal abnormalities and an unstable genome . Many amplifications and deletions occurred in different regions of the genome. For example, 1q23.1–1q21.1, 1p35, 19p13.11–19p13.2, and 6p22.1–6p21.31 amplified whilst 5q14.3–5q22.2, 13q13.2–13p14.3, and 5q12.3–5q13.2 are deleted [21, 22]. It has been showed that these modifications and deletions are related with deregulation of a sequence of molecular targets such as rapamycin (mTOR) and vascular endothelial growth factor (VEGF), cellular adhesion molecules, wingless-type MMTV integration site family (Wnt), and Hedgehog signaling pathways . One of the other aspects of osteosarcoma progression is the inactivation of tumor suppressor genes. For example, the alterations in tumor protein p53 (TP53) and retinoblastoma 1 (Rb1) in sporadic osteosarcoma is approximately 30 to 40 present . The Rb gene mutations resulted in the enhanced function of the transcription factor E2F. In primary osteosarcoma, the high levels of E2F1 have growth- suppressing effects such as p73 induction . The reduced expression of WW domain-containing oxidoreductase (WWOX) in many cancers which acts as a tumor suppressor, is related to aggressive properties and low prognosis . The deletion of the WWOX gene is observed in 30% of osteosarcoma cases which likely is an initial event in osteosarcoma pathogenesis .
Anti-tumor effects of melatonin
Another pre-clinical study, supported the melatonin exerts a cytostatic effect which lead to the cell accumulation in the G0/G1 phase or delaying in the entry to the S phase . Shen et al.  demonstrated that melatonin induced the number of cells in the G1 phase but diminished those in the S phase. Another study was shown the cycle detention and apoptosis occurred after the administration of melatonin in the HepG2 cell line . An important aspect of the anti-tumor effect of melatonin is its ability to induce apoptosis. Melatonin induces apoptosis just in tumor cells and leads to decreasing tumor cell size . In a study on ovarian cancer, it was shown that melatonin causes increasing expression levels of the cleaved caspase 3, Bax, p53, and decreasing expression levels of Bcl-2, thus progresses apoptosis . Wang J et al.  evaluated the effect of melatonin on MDA-MB-361 breast cancer cells. Results indicated that melatonin had pro-apoptotic effects which were accompanied via increasing of APAF 1 expression by simultaneously repressing the p300/NF-κB, COX-2/PGE2, and PI3K/Akt signaling. Melatonin is able to induce the releasing of cytochrome c and stimulated activities and cleavage of caspase 9 and 3.
In another study, it was observed that caspase 3, 9, 6, and 7 were activated and melatonin also increased the Bax expression levels and induces the liberation of cytochrome c . Recently, efforts have shifted to discover the role of melatonin in the prevention of tumor metastasis . In several types of cancer, it has been indicated that melatonin has also significant anti-metastatic effects such as its capacity to prevent the epithelial-to-mesenchymal transition (EMT) . The modulation of cell–matrix, cytoskeletal reorganization, and prohibition of angiogenesis are other anti-metastatic mechanisms affected by melatonin [52, 53, 54]. The epidermal growth factor receptor 2 (HER2) alongside Mapk/Erk signaling leads to the enhancement of metastasis and invasiveness of cancer cells. Utilization of melatonin considerably decreased the function of Mapk/Erk signaling . Also, melatonin exerts its anti-invasive activity though down regulation of the p38 pathway and detention of activity and expression of metalloproteinases-2 and -9 . Other beneficial actions of melatonin in cancer therapy are including reduction of oxidative stress and toxicity due to chemotherapy and radiotherapy . In addition, emerging data is showing that melatonin shows weak or no anti-cancer effects [57, 58, 59]. These studies indicated that melatonin could not be used as first line therapeutic agent in the treatment of various cancers. These studies recommended that melatonin could be employed as adjuvant therapy in combination with primary treatment agents and platforms.
Melatonin effects on bone cancer
The effects of melatonin on bone cancers open attractive horizons for many researchers. In this regards, several experimental studies have been conducted to assess the underlined mechanisms affected by melatonin in bone cancers. It is proven that bone metabolism is associated with melatonin levels. Melatonin has an effect on bone-linked cell proliferation [60, 61]. It has been showed that, in the specific time points, the levels of melatonin are low and it is related to high incidence of osteosarcoma. These finding hypotheses that melatonin may have an inhibitory effects on osteosarcoma cells [62, 63]. Several studies have shown the anti-proliferative effects of melatonin on the MG-63 osteosarcoma cells and have reported that the inhibitory activity of melatonin related to mitogen-activated kinases and AKT signaling [42, 63]. Melatonin interferes with the proliferation of osteosarcoma cells via modulation of various signaling pathways. Melatonin specifically inhibits the phosphoactivation of ERK1/2 . Also, these studies were demonstrated that the inhibitory function of melatonin correlated with the downregulation of cyclin CDK4 and D1 and of cyclin CDK1 and B1 [42, 63].
Liu et al.  demonstrated that the combination of melatonin and PD98059, a selective inhibitor, had a duplicated effect for blocking ERK1/2 activity. One of the mechanisms affected by melatonin to suppress osteosarcoma cells is the induction of apoptosis. Garcia-Santos et al.  observed that melatonin could induce apoptosis in the Ewing’s sarcoma cell line. Similarly, an in vitro study reported that melatonin led to the induction apoptotic cell death by applying the Fas/FasL system in Ewing’s sarcoma. Various studies reported that melatonin upregulated the death receptor Fas and its ligand FasL . This study also revealed that melatonin could transiently increase the number of intracellular oxidants and also activate the redox-regulated transcription factor NF-kB . Another study revealed that the combination of melatonin and vincristine could provide an acceptable synergistic effect and induced apoptosis via affecting on the extrinsic pathway in SK-N-MC cells. As well as, there was a significant enhancement in expression levels of caspase-3, -8, -9 and Bid when melatonin/vincristinein complex is used compared to the single treatments .
Experimental studies that investigated the role of melatonin in bone cancer
Type of bone cancer
Form of melatonin
Melatonin loaded nanoparticles (PLGA)
Inhibition of MG-63 proliferation and decrease cell viability
Melatonin combined with vincristine
50 µm–1 mM
Significant enhancement in the activation of Bid and caspase-3, -8, -9
(cell line SOSP-9607)
Reductions in GSH, tumor cell vitality, migration ability, adhesion ability, up-regulated acetylated-p53 and down-regulated SIRT1 and increase in the apoptotic index
4 mM–10 mM
Inhibition of the MG-63 proliferation and downregulation of cyclin D1,B1,E and CDK4, CDK1, CDK2
Melatonin/PD98059 and melatonin
Prohibition of the proliferation by significantly inhibited phosphorylation of ERK1/2
Inhibition of the JNK pathway and reduction chemokine CCL24
(A-673, TC-71, A-4573 cells)
Reversion ewing sarcoma metabolic profile that was related to its cytotoxicity
(SK-N-MC, TC-71 A673, SK-ES1, A4573)
Expression of Fas and its ligand Fas L, activation of the redox-regulated transcription
factor Nuclear factor-kappaB and enhance in intracellular oxidants
Osteosarcoma is known as high-grade primary bone malignancy. Despite the many available anti-tumor therapies, the 5-year survival rate is only 60–70%. The different strategies are used to treat osteosarcoma including the targeting of the altered transcription factors, cell proliferation regulators, apoptosis targets, and angiogenesis modulators, to date, due to the side effects related to the established treatments, researchers try to find new or develop therapeutic platforms to overcome to these current limitations. Due to the parallel incidence of osteosarcoma and melatonin levels, this hormone could be introduced as a new candidate for the treatment of osteosarcoma. Several experimental studies have reported the anti-cancer effects of melatonin against osteosarcoma. The results showed that melatonin can exert its anti-tumor properties through activation/inhibition various mechanisms such as induction of apoptosis, anti-proliferative, and anti-oxidant activities. Also, observing the positive effects of melatonin on preventing of the invasion and migration of osteosarcoma cells to other organs is a promising therapeutic strategy to the prevent osteosarcoma metastasis. Collectively, melatonin alone or in combination with other therapeutic agents may be a good option for osteosarcoma cancer treatment.
ZA contributed in conception, design and drafting of the manuscript. HF and HM contributed in data collection and manuscript drafting. ZA and HM oversaw the study. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was considered exempt by the KAUMS Institutional Review Board.
Consent for publication
The authors declare that they have no competing interests.
- 5.Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, et al. Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol. 2004;22(14):2873–6.PubMedCrossRefPubMedCentralGoogle Scholar
- 6.Casado-Zapico S, Rodriguez-Blanco J, Garcia-Santos G, Martin V, Sanchez-Sanchez AM, Antolin I, Rodriguez C. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res. 2010;48(1):72–80.PubMedCrossRefPubMedCentralGoogle Scholar
- 23.Liontos M, Niforou K, Velimezi G, Vougas K, Evangelou K, Apostolopoulou K, Vrtel R, Damalas A, Kontovazenitis P, Kotsinas A, et al. Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol. 2009;175(1):376–91.PubMedPubMedCentralCrossRefGoogle Scholar
- 32.Chiu YJ, Hour MJ, Jin YA, Lu CC, Tsai FJ, Chen TL, Ma H, Juan YN, Yang JS. Disruption of IGF1R signaling by a novel quinazoline derivative, HMJ30, inhibits invasiveness and reverses epithelial-mesenchymal transition in osteosarcoma U2 OS cells. Int J Oncol. 2018;52(5):1465–78.PubMedCentralGoogle Scholar
- 36.Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda, Md). 2014;29(5):325–33.Google Scholar
- 39.Paroni R, Terraneo L, Bonomini F, Finati E, Virgili E, Bianciardi P, Favero G, Fraschini F, Reiter RJ, Rezzani R, et al. Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. J Pineal Res. 2014;57(1):43–52.PubMedCrossRefPubMedCentralGoogle Scholar
- 51.Goncalves Ndo N, Colombo J, Lopes JR, Gelaleti GB, Moschetta MG, Sonehara NM, Hellmen E, Zanon Cde F, Oliani SM, Zuccari DA. Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines. PLoS ONE. 2016;11(3):e0150407.PubMedCrossRefGoogle Scholar
- 66.Maiese K, Chong ZZ, Shang YC, Wang S. Translating cell survival and cell longevity into treatment strategies with SIRT1. Roman J Morphol Embryol. 2011;52(4):1173–85.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.